Loading stock data…
Regeneron Pharmaceuticals (REGN)
$631.81-1.09 (-0.17%)
Market ClosedLast close Jun 29
Regeneron Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Regeneron Pharmaceuticals, Inc. in the Healthcare sector is trading at $631.81 with a market capitalization of $64.2B. Wall Street consensus targets $833.31 (28 analysts), implying a +31.9% move over the next 12 months. The stock is currently 23% below its 52-week high of $821.11, remaining 9.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +31.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.61B↓ | $3.88B↑ | $3.75B↑ | $3.68B↑ | $3.03B |
| Gross Profit | $2.94B↓ | $3.30B↑ | $3.23B↑ | $3.15B↑ | $2.56B |
| Operating Income | $744.80M↓ | $898.60M↓ | $1.11B↑ | $1.08B↑ | $591.70M |
| Net Income | $727.20M↓ | $844.60M↓ | $1.46B↑ | $1.39B↑ | $808.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$64.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.43%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.08%
Volume
Today's trading volume
715,219
Recent News
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with “generalized myasthenia gravis” who are anti-acetylcholine receptor antibody-positive. The company […]
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
Parabilis Medicines is ambitious, but it has Regeneron on its side already.
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
Kymera Therapeutics shares catapulted Thursday after the company wrapped enrollment in an eczema study six months ahead of expectations.